CommercialCoverageMedium impact
Daprodustat (Jesduvroq) (CPB 1044, reviewed 2026-01-27)
Aetna·Nephrology, Critical Care·Medical Policy
Effective date
Jan 27, 2026
We identified it
Aug 12, 2026
Summary
Aetna has established new coverage criteria for daprodustat (Jesduvroq), an oral medication for anemia in dialysis patients with CKD. The policy requires: (1) patients must have received dialysis for at least 4 months with pretreatment hemoglobin ≤11 g/dL for initial approval, (2) adequate iron stores (TSAT ≥20%) or concurrent iron therapy, and (3) no concurrent use with ESAs. All other indications are considered experimental. This is the first time Aetna has formally established coverage for this newly FDA-approved medication (February 2023).
Action Required
By February 27, 2026: Billing team must implement the following: (1) Update billing system to recognize HCPCS code J0889 (daprodustat oral 1 mg) for ESRD dialysis patients only; (2) Configure system to require documentation of: patient on dialysis ≥4 months, pretreatment hemoglobin ≤11 g/dL (initial approval) or current hemoglobin <12 g/dL (continuation), serum TSAT ≥20% within 3 months, and confirmation of no concurrent ESA use; (3) Add prior authorization requirement to claim submission workflow for all J0889 claims; (4) Update encounter templates for nephrology providers to capture required qualifying criteria at point of service; (5) Train billing staff to deny claims that lack evidence of iron sufficiency assessment or show concurrent ESA billing. Failure to implement these controls will result in claim denials and recoupment for non-compliant submissions.